Standout Papers

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery ... 2022 2026 2023 2024164
  1. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept (2022)
    Tamer Coşkun, Shweta Urva et al. Cell Metabolism

Immediate Impact

6 from Science/Nature 71 standout
Sub-graph 1 of 19

Citing Papers

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
2024 Standout
Tirzepatide for Obesity Treatment and Diabetes Prevention
2024 Standout
1 intermediate paper

Works of Libbey S. O′Farrell being referenced

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
2022 Standout

Author Peers

Author Last Decade Papers Cites
Libbey S. O′Farrell 246 140 271 243 16 600
Michael Lund 170 222 298 344 27 665
Nina Perwitz 198 126 146 396 17 693
Stephan Sachs 232 73 213 257 15 684
Holly E. Bates 156 60 198 182 14 531
H. L. Lickley 176 47 237 328 30 661
Shu-Chen Lu 404 94 221 141 12 665
Jun Namkung 231 44 146 291 21 690
Todd M. Suter 251 118 253 276 12 706
Ann-Marie Richard 251 59 120 238 11 522
Satyesh K. Sinha 243 125 149 127 23 691

All Works

Loading papers...

Rankless by CCL
2026